ORBIO CORPORATION | Oncotherapy Revolution by L-Glucose

Oncotherapy Revolution
By Isomer Organics

ABOUT

Delivering a therapeutic drug for intractable cancer to society with L-glucose, which is highly selective for cancer cells.

We are a medical startup company founded in Kyoto in 2018 with the goal of bringing a therapeutic drug for intractable cancer to society. We are researching cancer treatment technologies and creating cancer diagnostic and therapeutic drugs so that we can help patients suffering from cancer as soon as possible.

CORPORATE

MISSION

Leading patients with intractable cancer to a complete cure.

We aim to realize a new anti-cancer drug with L-glucose bound Orbio-molecules. We deliver the hope of complete cure beyond the diversity of intractable cancer.
Introducing a new treatment modality for cancer therapy.

We will implement “cancer-specific cell therapy” using L-glucose as a drug delivery system (DDS), which shows unprecedented high selectivity in cancer treatment.

TECHNOLOGY

VALUE

TEAM

Dr. EIICHI
YAMAGUCHI
CEO

Professor Emeritus, Kyoto University

Visiting Professor, Ritsumeikan University

Doctor of Science

Vice-President of The Japan Academic Society for Ventures and Entrepreneurs
Dr. HIDEKI
IIJIMA
Co-CEO/COO

Lecturer, the Graduate School of Medicine, Hirosaki University

Doctor of Engineering

Ph.D. in Management of Innovative Management
Dr. KATSUYA
YAMADA
CMO

ORBIO-Chaired Professor, Department of Molecular Transport, Hirosaki University Graduate School of Medicine

Visiting Professor, Osaka Metropolitan University Graduate School of Medicine

Ph.D. in Medicine; Councilor of the Physiological Society of Japan
KEI
YAMAGUCHI
CFO

Master of Commerce